Swedish Orphan Biovitrum AB (publ)

LSE:0MTD Stock Report

Market Cap: SEK 115.9b

Swedish Orphan Biovitrum Valuation

Is 0MTD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0MTD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

SEK 855.43
Fair Value
60.8% undervalued intrinsic discount
11
Number of Analysts

Below Fair Value: 0MTD (SEK335.46) is trading below our estimate of fair value (SEK855.43)

Significantly Below Fair Value: 0MTD is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0MTD?

Key metric: As 0MTD is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0MTD. This is calculated by dividing 0MTD's market cap by their current revenue.
What is 0MTD's PS Ratio?
PS Ratio4.2x
SalesSEK 27.85b
Market CapSEK 115.94b

Price to Sales Ratio vs Peers

How does 0MTD's PS Ratio compare to its peers?

The above table shows the PS ratio for 0MTD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average19.1x
GNS Genus
2.4x4.03%UK£1.6b
OXB Oxford Biomedica
4.9x19.58%UK£738.6m
BVXP Bioventix
8.2xn/aUK£107.6m
PRTC PureTech Health
61x-122.14%UK£297.8m
0MTD Swedish Orphan Biovitrum
4.2x9.61%SEK 115.9b

Price-To-Sales vs Peers: 0MTD is good value based on its Price-To-Sales Ratio (4.2x) compared to the peer average (19.1x).

Price to Sales Ratio vs Industry

How does 0MTD's PS Ratio compare vs other companies in the GB Biotechs Industry?

10 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.7.7x-3.4%
0MTD Swedish Orphan Biovitrum
 4.2x9.61%US$12.13b
GNS Genus
2.4x4.03%US$2.12b
OXB Oxford Biomedica
4.9x19.58%US$967.31m
0MTD 4.2xIndustry Avg. 7.7xNo. of Companies9PS020406080100+
10 CompaniesEstimated GrowthMarket Cap
Industry Avg.7.7x20.5%
0MTD Swedish Orphan Biovitrum
 4.2x47.75%US$12.13b
No more companies

Price-To-Sales vs Industry: 0MTD is good value based on its Price-To-Sales Ratio (4.2x) compared to the European Biotechs industry average (7.7x).

Price to Sales Ratio vs Fair Ratio

What is 0MTD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0MTD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.2x
Fair PS Ratio11.4x

Price-To-Sales vs Fair Ratio: 0MTD is good value based on its Price-To-Sales Ratio (4.2x) compared to the estimated Fair Price-To-Sales Ratio (11.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0MTD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 335.46
SEK 360.36
+7.42%
7.98%SEK 405.00SEK 308.00n/a11
Nov ’26SEK 326.40
SEK 343.36
+5.20%
10.63%SEK 400.00SEK 275.00n/a11
Oct ’26SEK 295.80
SEK 340.27
+15.03%
10.03%SEK 380.00SEK 275.00n/a11
Sep ’26SEK 288.52
SEK 341.18
+18.25%
10.11%SEK 380.00SEK 275.00n/a11
Aug ’26SEK 264.05
SEK 341.18
+29.21%
10.11%SEK 380.00SEK 275.00n/a11
Jul ’26SEK 284.55
SEK 346.17
+21.65%
10.30%SEK 383.00SEK 275.00n/a12
Jun ’26SEK 292.83
SEK 352.42
+20.35%
8.15%SEK 383.00SEK 285.00n/a12
May ’26SEK 296.39
SEK 355.25
+19.86%
8.44%SEK 385.00SEK 285.00n/a12
Apr ’26SEK 287.06
SEK 366.33
+27.62%
9.18%SEK 400.00SEK 285.00n/a12
Mar ’26SEK 314.52
SEK 368.42
+17.14%
9.55%SEK 405.00SEK 285.00n/a12
Feb ’26SEK 336.68
SEK 366.08
+8.73%
10.70%SEK 415.00SEK 275.00n/a12
Jan ’26SEK 316.62
SEK 359.73
+13.62%
10.64%SEK 400.00SEK 275.00n/a11
Dec ’25SEK 303.38
SEK 360.64
+18.87%
10.90%SEK 410.00SEK 275.00n/a11
Nov ’25SEK 333.19
SEK 351.27
+5.43%
11.22%SEK 410.00SEK 275.00SEK 326.4011
Oct ’25SEK 315.33
SEK 325.55
+3.24%
8.88%SEK 370.00SEK 250.00SEK 295.8011
Sep ’25SEK 318.77
SEK 328.00
+2.89%
8.47%SEK 370.00SEK 250.00SEK 288.5211
Aug ’25SEK 279.27
SEK 328.30
+17.56%
8.88%SEK 370.00SEK 250.00SEK 264.0510
Jul ’25SEK 285.80
SEK 329.60
+15.33%
6.21%SEK 370.00SEK 285.00SEK 284.5510
Jun ’25SEK 282.40
SEK 320.00
+13.31%
9.44%SEK 370.00SEK 252.00SEK 292.8310
May ’25SEK 285.40
SEK 317.22
+11.15%
9.79%SEK 370.00SEK 252.00SEK 296.399
Apr ’25SEK 267.20
SEK 317.70
+18.90%
9.65%SEK 370.00SEK 252.00SEK 287.0610
Mar ’25SEK 253.79
SEK 317.91
+25.26%
9.24%SEK 370.00SEK 252.00SEK 314.5211
Feb ’25SEK 297.17
SEK 316.20
+6.40%
8.02%SEK 345.00SEK 252.00SEK 336.6810
Jan ’25SEK 267.30
SEK 297.00
+11.11%
6.02%SEK 325.00SEK 252.00SEK 316.6210
Dec ’24SEK 248.83
SEK 293.00
+17.75%
6.99%SEK 325.00SEK 252.00SEK 303.3810
Nov ’24SEK 234.00
SEK 287.45
+22.84%
10.03%SEK 325.00SEK 222.00SEK 333.1911
SEK 359.35
Fair Value
6.6% undervalued intrinsic discount
11
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/24 22:30
End of Day Share Price 2025/11/24 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Swedish Orphan Biovitrum AB (publ) is covered by 28 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Xue ChenBarclays
Rosie TurnerBarclays